Information Provided By:
Fly News Breaks for October 5, 2018
HZNP
Oct 5, 2018 | 07:21 EDT
JMP Securities analyst Donald Ellis called Horizon Pharma's long-term, 72-week data on teprotumumab "a game-changer" that he believes will position the drug as a first-line therapy for treating thyroid eye disease, or TED. Ellis, who foresees a potential filing for teprotumumab in mid-2019 and potential approval in early 2020, keeps an Outperform rating and $22 price target on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.